MRA With Feraheme in HHT
Keywords
Abstract
Description
The safety of the use of gadolinium based contrast agents in MR is a concern for the FDA, with risks of development of nephrogenic systemic fibrosis and the more recent discovery of accumulation of gadolinium in the brain in patients who have received multiple prior MR scans.
Hereditary hemorrhagic telangiectasia (HHT) manifests with multiple vascular malformations (VMs) in the skin, mucous membranes and solid organs affecting the spine, brain, liver, gastrointestinal tract, pancreas, and lungs. The disease has an autosomal dominant inheritance and affects 1 in 5000 individuals.
Cerebral vascular malformations occur in 23 % of HHT patients, with a bleeding risk of 0.5% per year. Pulmonary AVMs occur in 15-50% of HHT patients, with a complication rate of 50% ranging from fatal hemoptysis or hemothorax to stroke or cerebral abscess. Liver vascular malformations are present in 32-78% of HHT patients.
The rationale for screening for vascular malformations is detection of a treatable lesion prior to the development of a fatal complication. The international guidelines currently recommend different first line screening tests in each organ: MRI for cerebral VMs, transthoracic echocardiography for pulmonary VMs, endoscopy for gastrointestinal VMs, Doppler US or CT for liver VMs.
Contrast enhanced magnetic resonance angiography (CE-MRA) may play an important role in the simultaneous whole body screening of vascular malformations. The advantages of CE-MRA include visualization of the entire body vasculature in one examination, high spatial resolution comparable to CT, no ionizing radiation and easy of multiplanar reconstructions.
Substituting a conventional gadolinium based contrast agent (GBCA) with an ultra small, super paramagnetic iron oxide agent (USPIO) e.g ferumoxytol, will eliminate any potential risk of developing nephrogenic systemic fibrosis. Since 2009, ferumoxytol ('Feraheme' Advanced Magnetics, Cambridge, MA) has been FDA approved for the treatment of iron deficiency anemia in adult patients with chronic kidney disease. The results of prior studies suggest that ferumoxytol is comparable to standard GBCAs for CE- MRA. Our experience with use of ferumoxytol to date suggests that it will be a superior agent for detection of vascular malformations in a range of vascular territories and that it will be uniquely capable of interrogating multiple territories in one sitting, due to its highly stable intravascular residence time.
Dates
Last Verified: | 12/31/2018 |
First Submitted: | 11/27/2016 |
Estimated Enrollment Submitted: | 11/27/2016 |
First Posted: | 11/29/2016 |
Last Update Submitted: | 01/22/2019 |
Last Update Posted: | 01/24/2019 |
Actual Study Start Date: | 10/31/2016 |
Estimated Primary Completion Date: | 10/31/2018 |
Estimated Study Completion Date: | 10/31/2018 |
Condition or disease
Intervention/treatment
Procedure: Feraheme group
Phase
Arm Groups
Arm | Intervention/treatment |
---|---|
Experimental: Feraheme group All patients enrolled in the study will receive Feraheme MRI/MRA to detect vascular malformations. Ferumoxytol in its standard concentration (510 mg in 17 cc) will be administered IV at 0.15-0.21 mg/kg prior to MRI/MRA. | Procedure: Feraheme group |
Eligibility Criteria
Ages Eligible for Study | 18 Years To 18 Years |
Sexes Eligible for Study | All |
Accepts Healthy Volunteers | Yes |
Criteria | Inclusion Criteria: - Definite diagnosis of HHT (clinically or genetically confirmed) - Known or suspected AVMs in the brain, lung, and/or liver - Use of ferumoxytol as an MR agent is clinically indicated Exclusion Criteria: - Age <18 - Unable to have MRI scan - Prior adverse reaction to ferumoxytol |
Outcome
Primary Outcome Measures
1. Presence or absence of AVM [Immediate]
Secondary Outcome Measures
1. Size of AVM [Immediate]
2. Location of AVM [Immediate]
3. Overall image quality score [Immediate]
4. Artifact score [Immediate]
5. Vessel definition score [Immediate]
6. Number of AVM feeding arteries [Immediate]
7. Dimension of largest AVM feeding artery [Immediate]
8. Number of AVM draining veins [Immediate]
9. Dimension of largest AVM draining vein [Immediate]
10. Dimension of aneurysmal sac [Immediate]